文献速递白血病

全口服Revumenib联合地西他滨和维奈克拉治疗复发/难治性AML的SAVE研究

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
PubMed 文献 · J Clin Oncol · 2026-06-11

这项I-II期研究评估了全口服Revumenib、地西他滨/西达尿苷和维奈克拉方案治疗12岁及以上复发/难治性AML患者,主要终点为RP2D和CRc率。

要点

  • 全口服Revumenib联合地西他滨/西达尿苷和维奈克拉在复发/难治性AML中CRc率达71%。
  • RP2D为Revumenib 160mg每日两次联合强CYP3A4抑制剂。
  • 常见≥3级不良事件为发热性中性粒细胞减少(36%)、肺部感染(21%)和血小板减少(21%)。

核心结论

  • 该联合方案在携带menin抑制敏感变异的经重度治疗的AML患者中,与高缓解率和持久缓解相关,且安全性可接受。

研究设计与样本

  • 给药方案:地西他滨/西达尿苷第1-5天,维奈克拉第1-14天,Revumenib每日两次第1-28天。
  • 主要目标为确定RP2D和评估CRc率。

主要发现

  • 40%患者为KMT2Ar,38%为NPM1mt,21%为NUP98r;中位既往治疗线数为2,52%既往接受过维奈克拉。
  • CRc率为71%,CR/CRh率为60%,其中80%经流式细胞术检测MRD阴性。
  • 所有患者中位CR/CRh持续时间为10.5个月;KMT2Ar未达到,NPM1mt为10.7个月,NUP98r为5.9个月。
  • ≥3级不良事件包括发热性中性粒细胞减少(36%)、肺部感染(21%)、血小板减少(21%);分化综合征发生率为10%(5%为3级),经糖皮质激素治疗缓解。
  • 13%患者出现menin结合位点新发突变。

关键数值与推荐

  • Revumenib的RP2D为160mg每日两次,联合强CYP3A4抑制剂。
  • CRc率为71%,CR/CRh率为60%,MRD阴性率为80%。
  • 所有患者中位CR/CRh持续时间为10.5个月,KMT2Ar未达到,NPM1mt为10.7个月,NUP98r为5.9个月。

临床怎么用

  • 对于携带KMT2Ar、NPM1mt或NUP98r的复发/难治性AML患者,可考虑全口服Revumenib联合地西他滨/西达尿苷和维奈克拉方案。
  • 治疗期间需监测分化综合征,发生率10%,可使用糖皮质激素处理。
  • 需关注发热性中性粒细胞减少、肺部感染和血小板减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Revumenib is an oral inhibitor of menin-KMT2A, a key dependency in acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar), NPM1 mutation (NPM1mt), or NUP98 rearrangement (NUP98r). Preclinical studies suggest synergy with BCL2 inhibition. METHODS: In this phase I-II study, we evaluated an all-oral regimen of revumenib, decitabine/cedazuridine, and venetoclax in patients 12 years and older with relapsed or refractory AML. Decitabine/cedazuridine was given on days 1-5, venetoclax on days 1-14, and revumenib twice daily on days 1-28. The primary objectives were to determine the recommended phase II dose (RP2D) and to assess efficacy according to the composite complete remission (CRc) rate. RESULTS: Forty-two patients were enrolled (median age, 40 years; range, 12-82) including 40% with KMT2Ar, 38% with NPM1mt, and 21% with NUP98r. Patients had a median of two prior lines of therapy; 52% had prior venetoclax. The RP2D of revumenib was 160 mg twice daily with a strong CYP3A4 inhibitor. Grade ≥3 adverse events included febrile neutropenia (36%), lung infection (21%), and thrombocytopenia (21%). Differentiation syndrome occurred in 10% (5% grade 3) and resolved with glucocorticoids. The CRc rate was 71%, and the CR or complete remission with partial hematologic recovery (CR/CRh) rate was 60%, with measurable residual disease negativity by flow cytometry in 80% of these patients. The median duration of CR/CRh for all patients was 10.5 months, not reached in KMT2Ar, 10.7 months in NPM1mt, and 5.9 months in NUP98r. Emergent mutations in the menin-binding site occurred in 13%. CONCLUSION: This combination was associated with high response rates and durable remissions, with an acceptable safety, in heavily pretreated patients with AML harboring alterations susceptible to menin inhibition.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Issa GC, Cuglievan B, El Hajjar G, et al. All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). J Clin Oncol. 2026. PMID: 42272166. doi:10.1200/JCO-26-01159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。